Certara

Blog

Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program

Learn how the FDA assessment aid streamlines oncology NDA/BLA reviews, what to include, and best…

CertaraMarch 17, 2026

Press Coverage Video

FDA Support Drives Shift Toward Bayesian Trial Design

Explore how Bayesian statistical methods are reshaping clinical trial design. Learn how FDA support, adaptive…

Danielle PillsburyMarch 13, 2026

Video

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Learn how model-informed drug development (MIDD) and quantitative systems pharmacology (QSP) support antibody-drug conjugate (ADC)…

CertaraMarch 13, 2026

Press Coverage

Single Pivotal Trials Demand Stronger Data and Risk Strategies

As regulators increasingly accept single pivotal trials for drug approval, sponsors must strengthen data quality,…

CertaraMarch 13, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Announcement

Certara Welcomes Arjun Bedi to its Board of Directors 

Certara has appointed Arjun Bedi to its Board of Directors. His life sciences expertise will…

CertaraMarch 12, 2026

Live Events

Certainty US 2026

CertaraMarch 11, 2026

Announcement

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

Certara near-term emissions reduction target approved to advance ESG efforts and drive measurable climate action…

CertaraMarch 11, 2026

Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

CertaraMarch 11, 2026

Webinar

What is new in Phoenix 8.8?

Danielle PillsburyMarch 9, 2026

Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program

FDA Support Drives Shift Toward Bayesian Trial Design

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Single Pivotal Trials Demand Stronger Data and Risk Strategies

Discovery & Development Europe 2026

Certara Welcomes Arjun Bedi to its Board of Directors

Certainty US 2026

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

What is new in Phoenix 8.8?

Newsletter sign up

Quick links

Solutions

Contact